Results 281 to 290 of about 44,151 (306)

Clinical pharmacology of carvedilol

The Clinical Investigator, 1992
Animal work has shown that carvedilol is a nonselective beta-blocking drug. It has a vasodilator action from alpha-receptor blockade, but there is evidence that it has further action to relax smooth muscle, possibly from calcium channel antagonism. Carvedilol is lipid soluble and 25% bioavailable, and it has a half-life of about 7 h.
R. J. Walden, B. R. Graham, Brian N. C. Prichard, B. Tomlinson   +3 more
openaire   +3 more sources

Hemodynamic profile of carvedilol

European Journal of Clinical Pharmacology, 1990
Several so-called multiple-action compounds have been developed, such as medroxalol (alpha and beta blockade, and beta-2 stimulation), celiprolol (alpha-2 and beta-1 blockade, and beta-2 stimulation) and carvedilol (beta blockade and vasodilatation) for the treatment of patients with arterial hypertension and with coronary heart disease.
Vinzenz Hombach, Siegfried Wieshammer, A. Schmidt, Martin Höher, T. Eggeling, Matthias Kochs, W. Haerer   +6 more
openaire   +3 more sources

Pharmacokinetics and Disposition of Carvedilol in Humans

Journal of Cardiovascular Pharmacology, 1987
Pharmacokinetics of carvedilol (C) have been studied in healthy volunteers after a single i.v. and oral administration, and the metabolic disposition after oral administration of 14C-labeled drug. C demonstrates dose-linear behavior. The absolute bioavailability reaches 24% probably due to a first-pass effect.
von Möllendorff E, Neugebauer G, Reiff K, Akpan W, Neubert P   +4 more
openaire   +3 more sources

The effects of carvedilol, metoprolol and propranolol on cisplatin-induced kidney injury

Drug and chemical toxicology (New York, N.Y. 1978), 2020
The β-adrenoceptor blockers may have anti-oxidant properties or induce β-arrestin recruitment beyond classical desensitization of receptor/G protein coupling, offering potential therapeutic benefits.
Abdolhamid Esmaeeli, Zahra Keshavarz, Firoozeh Dehdar, M. Assadi, M. Seyedabadi   +4 more
semanticscholar   +1 more source

Digoxin‐carvedilol interactions in children

Clinical Pharmacology & Therapeutics, 2003
Clinical Pharmacology & Therapeutics (2003) 73, P92–P92; doi:
Lee N. Benson, Gideon Koren, Savithiri Ratnapalan, Adriana Moldovan Costei, Kathryn Griffiths   +4 more
openaire   +4 more sources

Vasodilatory Effects of Carvedilol and Pindolol

Journal of Cardiovascular Pharmacology, 1987
The effects of three different nonselective beta-blockers on central and peripheral hemodynamics as well as on pulmonary function were compared in 13 healthy subjects (19-37 years). The subjects were given carvedilol 50 mg, pindolol 10 mg, propranolol 80 mg, and placebo orally twice daily for 1 week in a double-blind, crossover, randomized manner ...
Kirsti Tiihonen, A. Gordin, Stig Sundberg   +2 more
openaire   +3 more sources

Carvedilol promotes retinal ganglion cell survival following optic nerve injury via ASK1-p38 MAPK pathway.

CNS and Neurological Disorders - Drug Targets, 2020
Carvedilol, which is considered as a nonselective β-adrenoreceptor blocker, has many pleiotropic activities. It also causes great influence on neuroprotection because of its antioxidant ability.
Bei Liu, Yu-Jia Liu
semanticscholar   +1 more source

Carvedilol: A countermeasure to heart failure

Dimensions of Critical Care Nursing, 2001
Initially used primarily as an antihypertensive, the beta-blocker carvedilol is now being used to alleviate heart failure, significantly reducing hospitalizations and mortality. In this article, we discuss the pathophysiology of heart failure; carvedilol's action, long-term benefits, and administration; and potential short-term adverse effects.
Anna Barkman, Charlotte Pooler
openaire   +3 more sources

Protective Effects of Carvedilol in the Myocardium

The American Journal of Cardiology, 1997
Beta blockers have long been used in the treatment of systemic hypertension, where they effectively lower blood pressure and, in so doing, they decrease left ventricular hypertrophy. The sympathetic nervous system is activated in patients with congestive heart failure, and therefore it is logical that beta blockers may also provide benefit in these ...
Robert R. Ruffolo, Antoine Bril, Giora Z. Feuerstein   +2 more
openaire   +3 more sources

Effects of Carvedilol During Exercise

Journal of Cardiovascular Pharmacology, 1992
The effect of carvedilol on cardiovascular and physical performance parameters at rest and during exercise was evaluated in an open, uncontrolled study. Assessments were made at rest, at one-half anaerobic threshold (1/2AT), at AT, and at maximal work load (WLmax) before and after 3 weeks of treatment with 12.5 mg carvedilol once daily for 1 week ...
Erling Loefsjoegaard-Nilsson, Susan Krug-Gourley, Margareta Gunolf, Berndt Atmer   +3 more
openaire   +2 more sources